The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
J. D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
L. Thomas
No relevant relationships to disclose
I. N. Bondarenko
No relevant relationships to disclose
S. O'Day
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
J. S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Other Remuneration - Medarex
C. Garbe
Consultant or Advisory Role - Bristol-Myers Squibb; Genta; GlaxoSmithKline; Merck Sharp & Dohme; Roche; SOBI
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; SOBI
Research Funding - Bristol-Myers Squibb; Genta; Merck Sharp & Dohme; Roche; SOBI
S. Francis
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
R. A. Ibrahim
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
A. Hoos
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
C. Robert
Consultant or Advisory Role - Bristol-Myers Squibb